| 1 |
Bloem BR , Okun MS , Klein C . Parkinson's disease. Lancet, 2021, 397: 2284- 2303.
doi: 10.1016/S0140-6736(21)00218-X
|
| 2 |
Parkinson's Disease and Movement Disorders Group, Neurology Branch, Chinese Medical Association , Parkinson's Disease and Movement Disorders Group, Neurologist Branch, Chinese Medical Doctor Association . Chinese guidelines for the treatment of Parkinson's disease(fourth edition). Zhonghua Shen Jing Ke Za Zhi, 2020, 53: 973- 986.
doi: 10.3760/cma.j.cn113694-20200331-00233
|
|
中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第四版). 中华神经科杂志, 2020, 53: 973- 986.
doi: 10.3760/cma.j.cn113694-20200331-00233
|
| 3 |
Cheong JLY , de Pablo'Fernandez E , Foltynie T , Noyce AJ . The association between type 2 diabetes mellitus and Parkinson's disease. J Parkinsons Dis, 2020, 10: 775- 789.
doi: 10.3233/JPD-191900
|
| 4 |
Fralick M , Jenkins AJ , Khunti K , Mbanya JC , Mohan V , Schmidt MI . Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol, 2022, 18: 199- 204.
doi: 10.1038/s41574-021-00621-y
|
| 5 |
Sanz FJ , Solana-Manrique C , Lilao-Garzón J , Brito-Casillas Y , Muñoz-Descalzo S , Paricio N . Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila. FASEB J, 2022, 36: e22432.
|
| 6 |
Bayram E , Litvan I . Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. Brain, 2020, 143: 2868- 2871.
doi: 10.1093/brain/awaa287
|
| 7 |
Driver JA , Smith A , Buring JE , Gaziano JM , Kurth T , Logroscino G . Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care, 2008, 31: 2003- 2005.
doi: 10.2337/dc08-0688
|
| 8 |
Chohan H , Senkevich K , Patel RK , Bestwick JP , Jacobs BM , Ciga SB , Gan-Or Z , Noyce AJ . Type 2 diabetes as a determinant of Parkinson's disease risk and progression. Mov Disord, 2021, 36: 1420- 1429.
doi: 10.1002/mds.28551
|
| 9 |
Ou R , Wei Q , Hou Y , Zhang L , Liu K , Lin J , Jiang Z , Song W , Cao B , Shang H . Effect of diabetes control status on the progression of Parkinson's disease: a prospective study. Ann Clin Transl Neurol, 2021, 8: 887- 897.
doi: 10.1002/acn3.51343
|
| 10 |
De Pablo-Fernandez E , Sierra-Hidalgo F , Benito-León J , Bermejo-Pareja F . Association between Parkinson's disease and diabetes: data from NEDICES study. Acta Neurol Scand, 2017, 136: 732- 736.
doi: 10.1111/ane.12793
|
| 11 |
Lu L , Fu DL , Li HQ , Liu AJ , Li JH , Zheng GQ . Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One, 2014, 9: e85781.
doi: 10.1371/journal.pone.0085781
|
| 12 |
Lv YQ , Yuan L , Sun Y , Dou HW , Su JH , Hou ZP , Li JY , Li W . Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse mode. Transl Neurodegener, 2022, 11: 14.
doi: 10.1186/s40035-022-00288-z
|
| 13 |
Sharma S , Taliyan R . High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behav Brain Res, 2018, 351: 17- 23.
doi: 10.1016/j.bbr.2018.05.025
|
| 14 |
Athauda D , Maclagan K , Skene SS , Bajwa-Joseph M , Letchford D , Chowdhury K , Hibbert S , Budnik N , Zampedri L , Dickson J , Li Y , Aviles-Olmos I , Warner TT , Limousin P , Lees AJ , Greig NH , Tebbs S , Foltynie T . Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, 2017, 390: 1664- 1675.
doi: 10.1016/S0140-6736(17)31585-4
|
| 15 |
Hong JM , Choi ES , Park SY . Selective brain cooling: a new horizon of neuroprotection. Front Neurol, 2022, 13: 873165.
doi: 10.3389/fneur.2022.873165
|
| 16 |
Grieco M , Giorgi A , Gentile MC , d'Erme M , Morano S , Maras B , Filardi T . Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci, 2019, 13: 1112.
doi: 10.3389/fnins.2019.01112
|
| 17 |
Bayarsaikhan E , Bayarsaikhan D , Lee J , Son M , Oh S , Moon J , Park HJ , Roshini A , Kim SU , Song BJ , Jo SM , Byun K , Lee B . Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics. Int J Nanomedicine, 2016, 10: 281- 292.
doi: 10.2147/IJN.S95077
|
| 18 |
Song DW , Xin N , Xie BJ , Li YJ , Meng LY , Li HM , Schläppi M , Deng YL . Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. Int J Mol Med, 2014, 33: 736- 742.
doi: 10.3892/ijmm.2013.1604
|
| 19 |
Sergi D , Renaud J , Simola N , Martinoli MG . Diabetes, a contemporary risk for Parkinson's disease: epidemiological and cellular evidences. Front Aging Neurosci, 2019, 11: 302.
doi: 10.3389/fnagi.2019.00302
|
| 20 |
Papachristoforou E , Lambadiari V , Maratou E , Makrilakis K . Association of glycemic indices(hyperglycemia, glucose variability, and hypoglycemia)with oxidative stress and diabetic complications. J Diabetes Res, 2020, 7489795.
|
| 21 |
Su CJ , Shen Z , Cui RX , Huang Y , Xu DL , Zhao FL , Pan J , Shi AM , Liu T , Yu YL . Thioredoxin-Interacting Protein(TXNIP)regulates Parkin/PINK1-mediated mitophagy in dopaminergic neurons under high-glucose conditions: implications for molecular links between Parkinson's disease and diabetes. Neurosci Bull, 2020, 36: 346- 358.
doi: 10.1007/s12264-019-00459-5
|
| 22 |
Pérez-Taboada I , Alberquilla S , Martín ED , Anand R , Vietti-Michelina S , Tebeka NN , Cantley J , Cragg SJ , Moratalla R , Vallejo M . Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice. Mov Disord, 2020, 35: 1636- 1648.
doi: 10.1002/mds.28124
|
| 23 |
Renaud J , Bassareo V , Beaulieu J , Pinna A , Schlich M , Lavoie C , Murtas D , Simola N , Martinoli MG . Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. Neurobiol Aging, 2018, 69: 117- 128.
doi: 10.1016/j.neurobiolaging.2018.05.010
|
| 24 |
Kouli A , Camacho M , Allinson K , Williams-Gray CH . Neuroinflammation and protein pathology in Parkinson's disease dementia. Acta Neuropathol Commun, 2020, 8: 211.
doi: 10.1186/s40478-020-01083-5
|
| 25 |
Ho MS . Microglia in Parkinson's disease. Adv Exp Med Biol, 2019, 1175: 335- 353.
|
| 26 |
Li Y , Long W , Gao M , Jiao F , Chen Z , Liu M , Yu L . TREM2 regulates high glucose-induced microglial inflammation via the NLRP3 signaling pathway. Brain Sci, 2021, 11: 896.
doi: 10.3390/brainsci11070896
|
| 27 |
Gritsenko A , Green JP , Brough D , Lopez-Castejon G . Mechanisms of NLRP3 priming in inflammaging and age related diseases. Cytokine Growth Factor Rev, 2020, 55: 15- 25.
doi: 10.1016/j.cytogfr.2020.08.003
|
| 28 |
Gordon R , Albornoz EA , Christie DC , Langley MR , Kumar V , Mantovani S , Robertson AAB , Butler MS , Rowe DB , O'Neill LA , Kanthasamy AG , Schroder K , Cooper MA , Woodruff TM . Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med, 2018, 10: eaah4066.
doi: 10.1126/scitranslmed.aah4066
|
| 29 |
Söderbom G , Zeng BY . The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. Int Rev Neurobiol, 2020, 154: 345- 391.
|
| 30 |
Kuzan A . Toxicity of advanced glycation end products(Review). Biomed Rep, 2021, 14: 46.
doi: 10.3892/br.2021.1422
|
| 31 |
Khalid M , Petroianu G , Adem A . Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules, 2022, 12: 542.
doi: 10.3390/biom12040542
|
| 32 |
Chrysanthou M , Estruch IM , Rietjens IMCM , Wichers HJ , Hoppenbrouwers T . In vitro methodologies to study the role of advanced glycation end products(AGEs)in neurodegeneration. Nutrients, 2022, 14: 363.
doi: 10.3390/nu14020363
|
| 33 |
Uceda AB , Frau J , Vilanova B , Adrover M . Glycation of α-synuclein hampers its binding to synaptic-like vesicles and its driving effect on their fusion. Cell Mol Life Sci, 2022, 79: 342.
doi: 10.1007/s00018-022-04373-4
|
| 34 |
Miranda HV , El-Agnaf OMA , Outeiro TF . Glycation in Parkinson's disease and Alzheimer's disease. Mov Disord, 2016, 31: 782- 790.
doi: 10.1002/mds.26566
|
| 35 |
Long H , Zhang S , Zeng S , Tong Y , Liu J , Liu C , Li D . Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia. Cell Rep, 2022, 40: 111401.
doi: 10.1016/j.celrep.2022.111401
|
| 36 |
Deng Y , Zhang Y , Li Y , Xiao S , Song D , Qing H , Li Q , Rajput AH . Occurrence and distribution of salsolinol-like compound, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline(ADTIQ)in parkinsonian brains. J Neural Transm(Vienna), 2012, 119: 435- 441.
doi: 10.1007/s00702-011-0724-4
|
| 37 |
Cao Y , Li B , Ismail N , Smith K , Li T , Dai R , Deng Y . Neurotoxicity and underlying mechanisms of endogenous neurotoxins. Int J Mol Sci, 2021, 22: 12805.
doi: 10.3390/ijms222312805
|
| 38 |
Xie B , Lin F , Ullah K , Peng L , Ding W , Dai R , Qing H , Deng Y . A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. Biochem Biophys Res Commun, 2015, 459: 361- 366.
doi: 10.1016/j.bbrc.2015.02.069
|
| 39 |
Bonnet R , Pavlovic S , Lehmann J , Rommelspacher H . The strong inhibition of triosephosphate isomerase by the natural beta-carbolines may explain their neurotoxic actions. Neuroscience, 2004, 127: 443- 53.
doi: 10.1016/j.neuroscience.2004.05.002
|
| 40 |
Pomytkin I , Pinelis V . Brain insulin resistance: focus on insulin receptor-mitochondria interactions. Life(Basel), 2021, 11: 262.
|
| 41 |
Fiory F , Perruolo G , Cimmino I , Cabaro S , Pignalosa FC , Miele C , Beguinot F , Formisano P , Oriente F . The relevance of insulin action in the dopaminergic system. Front Neurosci, 2019, 13: 868.
doi: 10.3389/fnins.2019.00868
|
| 42 |
Iravanpour F , Dargahi L , Rezaei M , Haghani M , Heidari R , Valian N , Ahmadiani A . Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease. CNS Neurosci Ther, 2021, 27: 308- 319.
doi: 10.1111/cns.13609
|
| 43 |
Sharma SK , Chorell E , Steneberg P , Vernersson-Lindahl E , Edlund H , Wittung-Stafshede P . Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci Rep, 2015, 5: 12531.
doi: 10.1038/srep12531
|
| 44 |
Hong CT , Chen KY , Wang W , Chiu JY , Wu D , Chao TY , Hu CJ , Chau KYD , Bamodu OA . Insulin resistance promotes Parkinson's disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells, 2020, 9: 740.
doi: 10.3390/cells9030740
|
| 45 |
Ramasubbu K , Rajeswari VD . Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem, 2023, 478: 1307- 1324.
doi: 10.1007/s11010-022-04587-x
|